Felix Baker

VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA.

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases.

ConjuChem, Inc. is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides.

Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account.

Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA.

ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada.

Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY.

Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.

Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA.

ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada.

Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA.

Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The private company is based in Lexington, MA. The CEO of the company is Sanj K. Patel.